Greenwich Rx, Tomball, TX

Is Greenwich Rx registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Greenwich Rx hold a Texas pharmacy license?

The Texas State Board of Pharmacy lists license 35734 for GREENWICH RX, TOMBALL, status Active, as of Nov 15, 2026.

Has Greenwich Rx had a state board action or FDA letter?

FDA letters: no matching record found on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026; the page lists 1 Form 483 (Sep 9, 2026) for Greenwich Rx. State board actions: the Texas State Board of Pharmacy file dated Nov 15, 2026 does not mark prior disciplinary orders on license 35734.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Greenwich Rx
Location
Tomball, TX
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Sep 9, 2026
FDA Data Dashboard inspections
No matching site found
Form 483 text on this page
1 Form 483, 14 observations
State board records
License found: 35734, Active

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Greenwich Rx, a 503A facility, with 1 dated action.

Document
Sep 9, 2026Form 483483 issued 09/09/2026fda.gov

A Form 483 lists investigator observations, not a final FDA determination.

FDA inspection classifications and published Form 483s

No inspected site under this exact name and city was found in the FDA Data Dashboard on Nov 15, 2026, searching 12,593 US sites with a drug inspection ending Oct 1, 2008 to Oct 23, 2026. FDA may list the site under another legal name, so this is not a finding that it was never inspected.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 14 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Aug 17, 2026 to Sep 9, 2026: 14 observations

Firm on the cover
Greenwich Rx, 9733 Fm 2902 Rd . Suite 100, Tomball, TX 77375
FEI number
3043120213
Establishment type on the cover
Producer of sterile and non-sterile drug products
FDA district office on the cover
1201 Main Street, Suite 7200 Dallas, TX 75202
Matched to this page by
firm name, city and state on the cover; linked from actions page
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Use of ingredients not intended for pharmaceutical use in sterile drug production.

Specifically, your firm was found to use a reduced dietaiy supplement grade APis in the compounding of finished sterile drug product, Glutathione Injection 200mg/mL. For example the API, Glutathione (L) USP (Reduced) (Dietaiy Supplement Grade), Lot <Redacted B4>, Expiry <Redacted B4> was used in the compounding of the finished sterile drug, Glutathione Injection 200mg/mL Lot 0060061826-1, BUD 09-26-2026. This lot was dispensed to fill patient-specific prescriptions. The firm continues to receive this grade of API based on a review of supplier provided COAs for Glutathione (L) USP.

Observation 2

Your firm produced drugs while construction was underway in an adjacent area without adequate controls to prevent contamination of the production environment and product.

Specifically,

A. On 8/l7/2026, during a site walk-through, I found construction with sheet rock in areas surrounding a newly constructed ISO Classified modular Cleanroom Suite <Redacted B4> occurring at the same time as compounding activities within ISO <Redacted B4> modular cleanrooms (Suites <Redacted B4> located in the same general area separated by a wall not extended to the facility ceiling. Your firm's management reported construction activities had been occurring approximately three (3) weeks prior to the start of this FDA inspection. Your firm was compounding the sterile drugs, Tirzepatide 30mg/Bl2 0.5mg/mL (2.4mL) 30mg/0.5mg mg/mL, Lot number 0011081726-1 BUD 2026-11-25, Batch size <Redacted B4> vials and Semaglutide 10mg/B12 0.5mL (1.3mL) 10mg/0.5mg, Lot number 0005081726-1, BUD 2026-11-25, Batch size <Redacted B4> vials.

10mg/0.5mg, Lot number 0005081726-1, BUD 2026-11-25, Batch siz~4 vials. B. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Microbial contamination was present in the ISO 5 area and areas adjacent to production areas.

Specifically, during my review of your firm's environmental monitoring (EM) records, I found the following deficiencies:

A. During a review of your fnm's 2025 <Redacted B4> EM monitor sampling of the ISO Classified Cleanroom Suite found two (2) different occurrences where I CFU was found during ISO 5 LAFC surface sampling (Acceptance Limits ISO Class 5: <Redacted B4>. These include:

1. 10/9/2025: ISO 5 <Redacted B4> Buffer Hood -1 CFU; Compounded sterile product include;

a. SEMAGLUTIDE IMG, Bl2 0.5/ML, Lot 0002-100925-A, BUD 1/17/2026

b. SEMAGLUTIDE IMG, B12 0.5MG/ML, Lot 0002 -100925-A

c. SEMAGLUTIDE 4MG, Bl2 0.5MG/ML, Lot 0003-100925-A

d. SEMAGLUTIDE 6MG, B12 0.5MG/ML, Lot 0004-100925-A

e. BPC-157 3mg/mL, Lot 019-1 00925-A

f.

BPC157/TB500/KPV 3/3/3MG/ML (NO COPPER), Lot 0021-100925-A, BUD 1/17/2026

g. GHK-CU l 0mg/mL, Lot 0027-100925-A, BUD 1/17/2026

h. BPC, TB500, KPV 3mg/3mg/3mg/mL, Lot 0021-100925-A

BPC-1 57 3mg/mL, Lot 0019-1 00925-A

J.

TIRZEPATIDE l 0MG, B12 0.5/ML, Lot 0007-100925-A

2. 12/11/2025: ISO 5 <Redacted B4> Buffer Hood -l CFU; Compounded sterile product include;

a. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Personnel were observed conducting aseptic manipulations where the movement of "first air" in the ISO 5 area is blocked or disrupted.

Specifically, during compounding observations of your firm's technicians, I observed your firm's technicians reaching over open vials while filling and stoppering filled sterile vials using their sterile gloved hands in the processing of sterile finished drug products, Tirzepatide 30mg/B 12 0.5mg/mL (2.4mL) 30mg/0.5mg mg/mL, Lot number 0011081726-1 BUD 2026-11-25; and Semaglutide 10mg/B12 0.5mg/mL (1.3mL) 10mg/0.5mg, Lot number 0005081726-1, BUD 2026-11-25 having the potential of blocking first air within the ISO 5 LAFC. The rubber stoppers were removed from a non-sterile. <Redacted B4> bag that were originally stored in the approved supplier's sterile packaging.

Observation 5

J

f.

Observation 6

The facility design was observed to allow the influx of lesser quality air into a classified area containing higher quality air.

Specifically,

A. Your firm was found to be using 2 separate modular ISO classified cleanrooms designed with open vents existing into non-controlled/non-classified areas of the facility. I found ISO 8 Anteroom for Suite <Redacted B4> vent appeared to contain white foreign particulates in the flow path. The vent was being held open using a yellow/black handle screwdriver, which was on the opposite side of the ISO 8 Anteroom Cleanroom for Cleanroom Suite. Your firm's Compounding Manager reported that the contract cleanroom certifier had used the screwdriver to hold open the vent during an issue with balancing the ISO 8 Anteroom differential pressure.

B. I found what appeared to be white foreign particulates on the floor within your firm's ISO 8 gowning room of Cleanroom Suite along with the vent remaining in the open position directly in front of the outside shoe storage rack.

Observation 7

Specifically, I found during aseptic processing involving stoppering and capping using sterile gloves, your firm's technicians were using a <Redacted B4> disrupting unidirectional airflow within <Redacted B4> ISO 5 LAFC units within Cleanroom Suites <Redacted B4> during the processing of sterile drug products, Tirzepatide 30mg/Bl2 0.5mg/mL (2.4mL) 30mg/0.5mg mg/mL, Lot number 0011081726-1 BUD 2026-11-25; and Semaglutide 10mg/Bl2 0.5mg/mL (1.3mL) 10mg/0.5mg, Lot number 0005081726-1, BUD 2026-11-25.

Observation 8

Personnel infrequently changed and sanitized gloves to prevent contamination.

Specifically, your firm's technician was observed pushing trash into trashcan using their sterile gloves without performing a sterile glove change afterword. The technician disinfected their gloves and returned to the ISO 5 LAFC within ISO 7 Buffer Room to continue aseptic processing activities.

Observation 9

Lack of disinfection of supplies at each transition from areas of lower quality air to areas of higher quality air.

Specifically,

A. Your firm's technician was observed failing to disinfect components located within the ISO 7 Buffer Rooms <Redacted B4> prior to placing them into the ISO 5 LAFC unit.

B. Your firm's technicians in both ISO 7 Buffer Rooms suites during the aseptic processing of the sterile drug products, Tirzepatide 30mg/Bl2 0.5mg/mL (2.4mL) 30mg/0.5mg mg/mL, Lot number 0011081726-1 BUD 2026-11-25; and Semaglutide 10mg/Bl2 0.5mg/mL (1.3mL) 10mg/0.5mg, Lot number 0005081726-1, BUD 2026-11-25, was observed transfering stoppered trays of vials from LAFcQ (ISO 5 filling LAFC) through the ISO 7 Buffer Room, and into ISO 5 LAFqj (ISO 5 LAFC capping and crimping) without disinfecting the trays.

trays ofvials from LAFcQ (ISO 5 filling LAFC) through the ISO 7 Buffer Room, and into ISO 5 LAFqj (ISO 5 LAFC capping and crimping) without disinfecting the trays. C. ...

Read the full 483 (PDF on fda.gov)

Observation 10

Inadequate <Redacted B4> testing on <Redacted B4> used to sterilize drug products.

I

S pecifically, during a review of your firm's <Redacted B4> test of <Redacted B4> used in the compounding of finished drug sterile products, your firm failed to use calibrated gauge(s) and equipment to ensure adequate testing and <Redacted B4> were capable of meeting their intended use.

Observation 11

Compounding with components, containers or other materials that have not been verified to assure that they do not contribute endotoxin contamination that may be objectionable given the product's intended use.

Specifically, your fnm fail to <Redacted B4> glass beakers used in the formulation of bulk non-sterile drug products that undergo sterile <Redacted B4> to render bulk product sterile. Your firm's management reported that glassware is <Redacted B4> used. It is <Redacted B4> and wiped with sterile <Redacted B4> prior to use. Your firm's cleanroom manager reported a <Redacted B4> has been purchased for the processing of glassware. I found your firm's washed glassware used in the formulation and compounding of bulk non-sterile drug products are stored on a wire shelf in a non-controlled non-classified area directly in from of the entiy door of the facility. The glassware is positioned <Redacted B4> on the rack with no covering over the opening of the glassware.

Observation 12

Failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions.

Specifically, your firm failed to provide adequate rational evidence in support that media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions.

Observation 13

Personnel donned gowning apparel improperly, in a way that may have caused the gowning apparel to become contaminated.

Specifically, on 8/19/2026, two (2) technicians were observed donning their sterile gowns to enter the ISO 7 Cleanroom to strut aseptic processing. Sterile gowns worn by both technicians contacted the floor while donning rendering the gowns non-sterile. Additionally, poor sterile gloving techniques were found inadequate by the technicians contacting the non-sterile side of the glove using the sterile fingers of the opposite sterile glove.

Observation 14

Smoke studies were not performed under dynamic conditions.

Specifically,

A. Your firm's PIC and cleanroom manager, reported that they neither received <Redacted B4> viewed, nor approved any static or dynamic smoke studies for either Cleanroom Suites, <Redacted B4> following original certifications or recertifications since the firm began operating in June 2025 for the <Redacted B4> cleanrooms.

B. Your firm's compounding manager reported that no smoke studies during media fills were performed to assess laminar air flow conditions within any of the ISO 5 LAFCs, during aseptic manipulations and interventions to determine impact on finished sterile drug products.

State board of pharmacy records

The Texas State Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.

LicenseType as the board gives itName on the board recordCityStatusPrior disciplinary orders (file flag)
35734Community Sterile CompoundingGREENWICH RXTOMBALLActiveNo

What this covers: The file marks whether a license has prior disciplinary orders (column DISP ACTN, Y or N) but does not list them; the orders are on the board’s license lookup, which this index does not copy. The board says orders entered more than 10 years ago are not online.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.